DelSiTech Ltd Announces the Development of Novel Long-Acting Injectable Biologics for HIV Prevention

supported by the Bill & Melinda Gates Foundation


Turku, Finland – 12 March 2021: DelSiTech Ltd, a Finnish drug delivery and drug development company, today announced the development of long-acting controlled release biological drug products for human immunodeficiency virus (HIV), funded in part by the Bill & Melinda Gates Foundation.

DelSiTechTMSilica Matrix is an advanced, sustained and controlled release delivery technology with applications for both injectable therapies and locally applied dosage forms. In addition to enabling long-acting injectable formulations for small molecules, significantly prolonging treatment periods, DelSiTech’s technology is applicable to sensitive biological drugs, such as therapeutic monoclonal antibodies and other proteins.

“Combination anti-retroviral therapies have represented the mainstay of HIV management for decades. Biologics such as monoclonal antibodies offer a unique new immunological strategy for the management of HIV, holding the potential for a significant improvement in HIV prevention for millions of patients around the world” said Dr. Lasse Leino, CEO of DelSiTech. “With the continued support of the Bill & Melinda Gates Foundation, DelSiTech is at the forefront of developing novel long-lasting treatment options for those in need of HIV management, especially in low- and middle-income countries.”